Navigation Links
DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
Date:11/15/2012

armacokinetics and anti-tumor activity of VAL-083 in patients with histologically confirmed initial diagnosis of primary WHO Grade IV malignant glioma (GBM), now recurrent.  Patients with prior low-grade glioma or anaplastic glioma are eligible, if histologic assessment demonstrates transformation to GBM.  Patients with secondary brain tumors due to CNS metastases are also eligible for the study.

GBM patients must have been previously treated for GBM with surgery and/or radiation, if appropriate, and must have failed both Bevacizumab (Avastin®) and temozolomide (Temodar®), unless either or both are contra-indicated. 

Response to therapy and disease progression will be evaluated by MRI prior to each treatment cycle.  An initial phase of the study will involve dose escalation cohorts until a maximum tolerated dose (MTD) is established in the context of modern care.  Once the modernized dosing regimen has been established, additional patients will be enrolled at the MTD (or other selected optimum dosing regimen).

DelMar Pharma is conducting the study under the direction of Dr. Howard Burris at the Sarah Cannon Research Institute in Nashville, Tennessee with a second center in Sarasota, Florida. 

Please refer to clinicaltrials.gov identifier NCT01478178 for further details on this clinical trial.

About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment o
'/>"/>

SOURCE Del Mar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auspex Pharmaceuticals Receives U.S. Patent on Novel JAK Inhibitor SD-900
2. Access Pharmaceuticals To Host Third Quarter Investor Call on Wednesday, November 28th
3. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
4. Cardioxyl Pharmaceuticals Raises $28 Million In Series B Financing Led By OrbiMed Advisors
5. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
6. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
7. Frost & Sullivan: Lack of Proper Price Regulation for Pharmaceuticals
8. Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
9. Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
10. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
11. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... THOUSAND OAKS, Calif. , Oct. 17, 2014 /PRNewswire/ ... appointment of R. Sanders Williams , M.D., president ... L. Mahley Distinguished Professor.  "We are ... the Amgen Board," said Robert A. Bradway , ... deep and distinguished experience in academic medicine and his ...
(Date:10/17/2014)... , October 17, 2014 ... Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has announced the ... : North American Automated External Defibrillators ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The report North ... analyzes the market of devices based ...
(Date:10/17/2014)... 2014  UBM Medica US announces that Endocrinology ... other clinicians who treat patients with type 2 ... use of insulin .  Nearly all ... therapy – daily injections of one or more ... the function of pancreatic beta cells. Insulin is a ...
Breaking Medicine Technology:Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3
... SUNNYVALE, Calif., Feb. 28, 2011 /PRNewswire/ ... company developing innovative technologies in diabetes management, announced that ... Silicon Valley Bank and ... used to help complete clinical trials and commercialize POGO™, ...
... Feb. 28, 2011 Advanced Cell Diagnostics, Inc. ... study utilizing RNAscope™ technology to detect human papillomavirus ... head and neck cancer. HPV status determined by ... patient outcome and highly concordant with that determined ...
Cached Medicine Technology:Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 2Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 3ACD Announces Clinical Study Results Using its RNAscope™ Technology 2ACD Announces Clinical Study Results Using its RNAscope™ Technology 3
(Date:10/20/2014)... (PRWEB) October 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sit and Slim ... 10 not to purchase or use Sit and Slim II ... Slim II is promoted as weight loss product on various ... from the market in 2010 for safety reasons, can significantly ...
(Date:10/20/2014)... October 20, 2014 Based on ... the only imaging assays capable of determining DNA ... test.  With these three dimensions of high-resolution data, ... detect the widest range of disease-causing genetic rearrangements, ... by other genomic tools, including today’s advanced sequencing ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 It’s hard to ... many orphans and vulnerable children around the world, it’s a ... some people, many children are forced to walk barefoot on ... their families or play with their friends. , Buckner ... with Air1 Radio in October to encourage support ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... , ST. LOUIS, Aug. 24 ... herbicide Atrazine have attorney and clean water advocate Steve Tillery ... and accountability for the herbicide,s manufacturers. , , ... the New York Times and the Peoria Journal Star have ...
... , , , OAKLAND, ... LATINA Style magazine on the publication,s list of the 50 ... , The LATINA Style survey, now in ... the value of diversity in the workplace, and identifies the corporations in ...
... Institute of Allergy and Infectious Diseases (NIAID), a component ... applications for a new initiative to establish a consortium ... these cooperative centerswhich together will receive funding up to ... immune system under normal conditions and to understand how ...
... - Concussions, whether from an accident, sporting event, or ... mental processes. Scientists have debated for centuries whether concussions ... changes that merely impair the way brain cells function, ... at Albert Einstein College of Medicine of Yeshiva University ...
... State University study shows that invigorated and dedicated employees ... home life. K-State psychology researchers studied how positive ... interactions. They found that employees who are engaged in ... dedication and absorption in daily activities, have better moods ...
... , SWARTZ CREEK, Mich., Aug. ... Health Services Division is partnering with CareSource in Ohio to ... outcomes and reduce healthcare costs associated with the disease. As ... is focused on the early identification and treatment of their ...
Cached Medicine News:Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 3Health News:Kaiser Permanente Named 2009 Company of the Year by LATINA Style Magazine 2Health News:Kaiser Permanente Named 2009 Company of the Year by LATINA Style Magazine 3Health News:NIAID to fund new human immune profiling research centers 2Health News:Strong link found between concussions and brain tissue injury 2Health News:Strong link found between concussions and brain tissue injury 3Health News:Researchers find that employees who are engaged in their work have happier home life 2Health News:Diplomat Specialty Pharmacy Partners With CareSource -- Launches Chronic Kidney Disease Management Program with Ohio Plan 2
... products are offered as 1-piece or modular, ... modular instruments may be customized with handles ... ratchets, insulation and flush ports. Many standard ... specifications may affect delivery times. , ...
... The Featured Products are ... Mediflex and are offered ... in regular or extra ... equipped with insulation, flush ...
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
Medicine Products: